Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children A Randomized Clinical Trial

被引:133
作者
Yanovski, Jack A. [1 ]
Krakoff, Jonathan [2 ]
Salaita, Christine G. [3 ]
McDuffie, Jennifer R. [1 ]
Kozlosky, Merel [3 ]
Sebring, Nancy G. [3 ]
Reynolds, James C. [4 ]
Brady, Sheila M. [1 ]
Calis, Karim A. [1 ,5 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Unit Growth & Obes, Program Dev Endocrinol & Genet, Bethesda, MD 20892 USA
[2] Natl Inst Diabet & Digest & Kidney Dis NIDDK, Phoenix Epidemiol & Clin Res Branch, Bethesda, MD USA
[3] NIH, Dept Nutr, Hatfield Clin Res Ctr, Bethesda, MD 20892 USA
[4] NIH, Dept Diagnost Radiol & Imaging Sci, Hatfield Clin Res Ctr, Bethesda, MD 20892 USA
[5] NIH, Dept Pharm, Hatfield Clin Res Ctr, Bethesda, MD 20892 USA
关键词
FAMILY-BASED TREATMENT; 10-YEAR FOLLOW-UP; METABOLIC SYNDROME; PEDIATRIC OBESITY; RISK-FACTORS; MASS INDEX; GLUCOSE-TOLERANCE; CHILDHOOD OBESITY; DOUBLE-BLIND; ADOLESCENTS;
D O I
10.2337/db10-1185
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-Metformin can decrease adiposity and ameliorate obesity-related comorbid conditions, including abnormalities in glucose homeostasis in adolescents, but there are few data evaluating the efficacy of metformin among younger children. Our objective was to determine whether metformin treatment causes weight loss and improves obesity-related comorbidities in obese children, who are insulin-resistant. RESEARCH DESIGN AND METHODS-This study was a randomized double-blind placebo-controlled trial consisting of 100 severely obese (mean BMI 34.6 +/- 6.6 kg/m(2)) insulin-resistant children aged 6-12 years, randomized to 1,000 mg metformin (n = 53) or placebo (n = 47) twice daily for 6 months, followed by open-label metformin treatment for 6 months. All children and their parents participated in a monthly dietitian-administered weight-reduction program. RESULTS-Eighty-five percent completed the 6-month randomized phase. Children prescribed metformin had significantly greater decreases in BMI (difference -1.09 kg/m(2), CI -1.87 to -0.31, P = 0.006), body weight (difference -3.38 kg, CI -5.2 to -1.57, P < 0.001), BMI Z score (difference between metformin and placebo groups -0.07, CI -0.12 to -0.01, P = 0.02), and fat mass (difference -1.40 kg, CI -2.74 to -0.06, P = 0.04). Fasting plasma glucose (P = 0.007) and homeostasis model assessment (HOMA) insulin resistance index (P = 0.006) also improved more in metformin-treated children than in placebo-treated children. Gastrointestinal symptoms were significantly more prevalent in metformin-treated children, which limited maximal tolerated dosage in 17%. During the 6-month open-label phase, children treated previously with placebo decreased their BMI Z score; those treated continuously with metformin did not significantly change BMI Z score furl her. CONCLUSIONS-Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program. Diabetes 60:477-485, 2011
引用
收藏
页码:477 / 485
页数:9
相关论文
共 51 条
  • [1] Childhood Overweight Status Predicts Diabetes at Age 21 Years: A Follow-up Study
    Al Mamun, Abdullah
    Cramb, Susanna M.
    O'Callaghan, Michael J.
    Williams, Gail M.
    Najman, Jake M.
    [J]. OBESITY, 2009, 17 (06) : 1255 - 1261
  • [2] Allen HF, 2005, J PEDIATR ENDOCR MET, V18, P761
  • [3] Diagnosing insulin resistance by simple quantitative methods in subiects with normal glucose metabolism
    Ascaso, JF
    Pardo, S
    Real, JT
    Lorente, RI
    Priego, A
    Carmena, R
    [J]. DIABETES CARE, 2003, 26 (12) : 3320 - 3325
  • [4] Atabek ME, 2008, J PEDIATR ENDOCR MET, V21, P339
  • [5] Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion
    August, Gilbert P.
    Caprio, Sonia
    Fennoy, Ilene
    Freemark, Michael
    Kaufman, Francine R.
    Lustig, Robert H.
    Silverstein, Janet H.
    Speiser, Phyllis W.
    Styne, Dennis M.
    Montori, Victor M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (12) : 4576 - 4599
  • [6] Effects of sibutramine treatment in obese adolescents - A randomized trial
    Berkowitz, Robert I.
    Fujioka, Ken
    Daniels, Stephen R.
    Hoppin, Alison G.
    Owen, Stanford
    Perry, Arlette C.
    Sothern, Melinda S.
    Renz, Cheryl L.
    Pirner, Mark A.
    Walch, Julia K.
    Jasinsky, Olga
    Hewkin, Ann C.
    Blakesley, Vicky A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 145 (02) : 81 - 90
  • [7] Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome
    Bridger, T
    MacDonald, S
    Baltzer, F
    Rodd, C
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2006, 160 (03): : 241 - 246
  • [8] Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance
    Burgert, Tania S.
    Duran, Elvira J.
    Goldberg-Gell, Rachel
    Dziura, James
    Yeckel, Catherine W.
    Katz, Stuart
    Tamborlane, William V.
    Caprio, Sonia
    [J]. PEDIATRIC DIABETES, 2008, 9 (06) : 567 - 576
  • [9] Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up
    Cicero, AFG
    Dormi, A
    Nascetti, S
    Panourgia, MP
    Grandi, E
    D'Addato, S
    Gaddi, A
    [J]. DIABETIC MEDICINE, 2005, 22 (09) : 1263 - 1266
  • [10] CIGOLINI M, 1984, DIABETES METAB, V10, P311